JohnsonD.W.Peritoneal dialysis. In: McDonaldS.P., RussG.R., eds. ANZDATA Registry Report 2003.Adelaide, Australia: Australian and New Zealand Dialysis and Transplant Registry; 2004: 39–54.
2.
FoleyR.N., ParfreyP.S., SarnakM.J.Epidemiology of cardiovascular disease in chronic renal disease.J Am Soc Nephrol1998; 9(Suppl 12): S16–S23.
3.
KennedyR., CaseC., FathiR., JohnsonD., IsbelN., MarwickT.H.Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease?Am J Med2001; 110: 198–204.
4.
StenvinkelP., HeimburgerO., PaultreF., DiczfalusyU., WangT., BerglundL.Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure.Kidney Int1999; 55: 1899–911.
5.
ParkJ.S., KimS.B.C-reactive protein as a cardiovascular risk factor and its therapeutic implications in end-stage renal disease patients.Nephrology (Carlton)2003; 8(Suppl): S40–9.
6.
PanichiV., MiglioriM., De PietroS., TaccolaD., BianchiA.M., GiovanniniL.C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure.Nephron2002; 91: 594–600.
7.
HerzigK.A., PurdieD.M., BrownA.M., ChangW., HawleyC.M., IsbelN.M.Is C-reactive protein a useful prognostic marker in peritoneal dialysis patients?J Am Soc Nephrol2001; 12: 814–21.
8.
ZimmermannJ., HerrlingerS., PruyA., MetzgerT., WannerC.Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.Kidney Int1999; 55: 648–58.
9.
YeunJ.Y., LevineR.A., MantadilokV., KaysenG.A.C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients.Am J Kidney Dis2000; 35: 469–76.
10.
WangA.Y., WangM., WooJ., LamC.W., LuiS.F., LiP.K.Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients.J Am Soc Nephrol2004; 15: 2186–94.
11.
KaysenG.A., EiserichJ.P.Characteristics and effects of inflammation in end-stage renal disease.Semin Dial2003; 16: 438–46.
12.
StenvinkelP.Inflammation in end-stage renal failure: Could it be treated?Nephrol Dial Transplant2002; 17(Suppl 8): 33–8.
13.
RidkerP.M., CushmanM., StampferM.J., TracyR.P., HennekensC.H.Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.N Engl J Med1997; 336: 973–9.
14.
KoenigW., SundM., FrohlichM., FischerH.G., LowelH., DoringA.C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.Circulation1999; 99: 237–42.
15.
DaneshJ., WhincupP., WalkerM., LennonL., ThomsonA., ApplebyP.Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses.BMJ2000; 321: 199–204.
16.
SattarN., GawA., ScherbakovaO., FordI., O'ReillyD.S., HaffnerS.M.Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.Circulation2003; 108: 414–19.
17.
IsekiK., TozawaM., YoshiS., FukiyamaK.Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients.Nephrol Dial Transplant1999; 14: 1956–60.
18.
NohH., LeeS.W., KangS.W., ShinS.K., ChoiK.H., LeeH.Y.Serum C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients.Perit Dial Int1998; 18: 387–94.
19.
HaubitzM., BrunkhorstR.C-reactive protein and chronic Chlamydia pneumoniae infection—long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis.Nephrol Dial Transplant2001; 16: 809–15.
20.
WangA.Y., WooJ., LamC.W., WangM., SeaM.M., LuiS.F.Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients?J Am Soc Nephrol2003; 14: 1871–9.
21.
KimS.B., MinW.K., LeeS.K., ParkJ.S., HongC.D., YangW.S.Persistent elevation of C-reactive protein and ischemic heart disease in patients with continuous ambulatory peritoneal dialysis.Am J Kidney Dis2002; 39: 342–6.
22.
KaysenG.A., DubinJ.A., MullerH.G., RosalesL.M., LevinN.W.The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group.Kidney Int2000; 58: 346–52.
23.
TsirpanlisG., BagosP., IoannouD., BletaA., MarinouI., LagouranisA.The variability and accurate assessment of microinflammation in haemodialysis patients.Nephrol Dial Transplant2004; 19: 150–7.
24.
FineA.Relevance of C-reactive protein levels in peritoneal dialysis patients.Kidney Int2002; 61: 615–20.
25.
AtesK., AtesA., EkmekciY., NergizogluG.The time course of serum C-reactive protein is more predictive of mortality than its baseline level in peritoneal dialysis patients.Perit Dial Int2005; 25: 256–68.
26.
AlbertM.A., DanielsonE., RifaiN., RidkerP.M.Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study.JAMA2001; 286: 64–70.
27.
ChangJ.W., YangW.S., MinW.K., LeeS.K., ParkJ.S., KimS.B.Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients.Am J Kidney Dis2002; 39: 1213–17.
28.
HoldaasH., FellstromB., JardineA.G., HolmeI., NybergG., FauchaldP.Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial.Lancet2003; 361: 2024–31.
29.
IkonomidisI., AndreottiF., EconomouE., StefanadisC., ToutouzasP., NihoyannopoulosP.Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin.Circulation1999; 100: 793–8.
30.
KimS.B., LeeS.K., MinW.K., ChiH.S., ParkJ.S.Lack of effects of low-dose aspirin on high-sensitivity C-reactive protein, hemostatic factors, and troponin T in CAPD patients.Perit Dial Int2002; 22: 721–3.
31.
RuilopeL.M., SalvettiA., JamersonK., HanssonL., WarnoldI., WedelH.Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study.J Am Soc Nephrol2001; 12: 218–25.
BoazM., SmetanaS., WeinsteinT., MatasZ., GafterU., IainaA.Secondary Prevention with Antioxidants of Cardiovascular Disease in Endstage Renal Disease (SPACE): Randomised placebo-controlled trial.Lancet2000; 356: 1213–18.
34.
YusufS., DagenaisG., PogueJ., BoschJ., SleightP.Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators.N Engl J Med2000; 342: 154–60.
35.
ZoccaliC., MallamaciF., TripepiG.Atherosclerosis in dialysis patients: Does Chlamydia pneumoniae infection contribute to cardiovascular damage?Nephrol Dial Transplant2002; 17(Suppl 8): 25–8.
